ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal aromatase inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 2
SUBSTANCE
Letrozole
Introducing Mono-Femara, a powerful nonsteroidal aromatase inhibitor designed to block estrogen synthesis and combat hormone-related cancers. As a cutting-edge third-generation agent, Mono-Femara selectively and reversibly inhibits aromatase, effectively stunting the growth of estrogen-dependent breast cancer cells.
Aromatase, a crucial cytochrome P-450 enzyme present in various tissues, including premenopausal ovaries, the liver, and breast tissues, catalyzes the conversion of androgens like androstenedione and testosterone into estrogens such as estrone and estradiol. By competitively binding to the heme component of this enzyme, Mono-Femara reduces estrogen production without interfering with the synthesis of other vital hormones like mineralocorticoids or corticosteroids. Unlike tamoxifen, which blocks estrogen receptors, Mono-Femara tackles the root cause by inhibiting estrogen production directly.
Approved by the FDA for the treatment of local or metastatic breast cancer in postmenopausal women with hormone receptor-positive or unknown receptor status, Mono-Femara is a game-changer in oncology. While it may lead to side effects associated with decreased estrogen levels, such as the risk of osteoporosis with long-term use, doctors often prescribe adjunct therapies like Fosamax to mitigate this concern.
Mono-Femara has demonstrated the ability to lower estrogen levels by an impressive 98% while simultaneously boosting testosterone levels. This makes it a favored choice among athletes and bodybuilders looking to reduce water retention and prevent gynecomastia during steroid cycles. However, it?s essential to note that exceeding doses of 2.5 mg/day may temporarily diminish libido, and prolonged use beyond 5 mg/day may potentially lead to kidney complications.
Moreover, Mono-Femara has been shown to delay the fusion of growth plates in adolescents, thereby enhancing the efficacy of growth hormone treatments, making it a valuable option for addressing short stature in children and teens.